Search: onr:"swepub:oai:DiVA.org:miun-51257" >
Colchicine for the ...
Colchicine for the treatment of patients with COVID-19 : an updated systematic review and meta-analysis of randomised controlled trials
-
Cheema, H. A. (author)
-
Jafar, U. (author)
-
Shahid, A. (author)
-
show more...
-
Masood, W. (author)
-
Usman, M. (author)
-
Hermis, A. H. (author)
-
Naseem, M. A. (author)
-
Sahra, S. (author)
-
Sah, R. (author)
-
- Lee, Ka Yiu (author)
- Mittuniversitetet,Institutionen för hälsovetenskaper (HOV),Swedish Winter Sports Research Centre
-
show less...
-
(creator_code:org_t)
- BMJ, 2024
- 2024
- English.
-
In: BMJ Open. - : BMJ. - 2044-6055. ; 14:4
- Related links:
-
https://doi.org/10.1...
-
show more...
-
https://miun.diva-po... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- OBJECTIVES: We conducted an updated systematic review and meta-analysis to investigate the effect of colchicine treatment on clinical outcomes in patients with COVID-19. DESIGN: Systematic review and meta-analysis. DATA SOURCES: We searched PubMed, Embase, the Cochrane Library, medRxiv and ClinicalTrials.gov from inception to January 2023. ELIGIBILITY CRITERIA: All randomised controlled trials (RCTs) that investigated the efficacy of colchicine treatment in patients with COVID-19 as compared with placebo or standard of care were included. There were no language restrictions. Studies that used colchicine prophylactically were excluded. DATA EXTRACTION AND SYNTHESIS: We extracted all information relating to the study characteristics, such as author names, location, study population, details of intervention and comparator groups, and our outcomes of interest. We conducted our meta-analysis by using RevMan V.5.4 with risk ratio (RR) and mean difference as the effect measures. RESULTS: We included 23 RCTs (28 249 participants) in this systematic review. Colchicine did not decrease the risk of mortality (RR 0.99; 95% CI 0.93 to 1.05; I2=0%; 20 RCTs, 25 824 participants), with the results being consistent among both hospitalised and non-hospitalised patients. There were no significant differences between the colchicine and control groups in other relevant clinical outcomes, including the incidence of mechanical ventilation (RR 0.75; 95% CI 0.48 to 1.18; p=0.22; I2=40%; 8 RCTs, 13 262 participants), intensive care unit admission (RR 0.77; 95% CI 0.49 to 1.22; p=0.27; I2=0%; 6 RCTs, 961 participants) and hospital admission (RR 0.74; 95% CI 0.48 to 1.16; p=0.19; I2=70%; 3 RCTs, 8572 participants). CONCLUSIONS: The results of this meta-analysis do not support the use of colchicine as a treatment for reducing the risk of mortality or improving other relevant clinical outcomes in patients with COVID-19. However, RCTs investigating early treatment with colchicine (within 5 days of symptom onset or in patients with early-stage disease) are needed to fully elucidate the potential benefits of colchicine in this patient population. PROSPERO REGISTRATION NUMBER: CRD42022369850.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)
Keyword
- CLINICAL PHARMACOLOGY
- COVID-19
- VIROLOGY
Publication and Content Type
- ref (subject category)
- for (subject category)
Find in a library
-
BMJ Open
(Search for host publication in LIBRIS)
To the university's database
- By the author/editor
-
Cheema, H. A.
-
Jafar, U.
-
Shahid, A.
-
Masood, W.
-
Usman, M.
-
Hermis, A. H.
-
show more...
-
Naseem, M. A.
-
Sahra, S.
-
Sah, R.
-
Lee, Ka Yiu
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Basic Medicine
-
and Pharmacology and ...
- Articles in the publication
-
BMJ Open
- By the university
-
Mid Sweden University